In the latest episode of The Line Podcast, recorded on July 10, 2026, Matt Gurney and Jen Gerson begin with a discussion of a recent Wall Street Journal piece highlighting Prime Minister Mark Carney’s role in pulling Europe back toward a more realistic strategic footing and away from its longstanding dependence on the United States. Canada, and Carney in particular, appear to be taking an unexpectedly prominent leadership role. Your hosts wonder what Washington’s response will be, and whether the White House will decide that Canada needs to be reminded who’s boss.

This episode is brought to you by Fractional Execs Canada. Need help with a serious business problem? As Canadian businesses grow they often require expert help to solve key business challenges. Fractional Execs Canada have assembled a team of experienced strategists, implementors, sales and marketing operators that can help transform your business into a growth engine. They match you with the right person, or team to move your business forward at a pace your business can manage.

Talk to Fractional Execs Canada and discover a better, more collaborative way to take your business and your ‘busyness’ in a better direction. Canadian expertise to support the growth of Canadian businesses. Build your business with those that know how.

Find them Fractional-Execs.ca.

Next, they turn to the proposed Canadian Shield pipeline. On strictly commercial grounds, the project may not make much sense. But Matt and Jen argue that economics may no longer be the primary point. The proposal sends a signal that Canada is prepared to build the infrastructure needed to stand more independently if circumstances require it. That message has value all on its own. As Matt puts it, borrowing from the movie Contact: “Why build one when you can build two at twice the price?”

This episode is brought to you by BioCanRx, a federally-funded Canadian not-for-profit research network bringing cutting edge cancer immunotherapy research from Canadian labs to patients in clinical trials –– all in Canada.

A drug that can treat your cancer is being tested in a Canadian clinical trial, but can you access it? Depends — where do you live? Clinical trials taking place in Canada usually open sites in major centers with research hospitals. Smaller hospitals face many challenges including having enough know-how to deliver experimental therapies, and administrative, legal, and regulatory responsibilities that come with a trial. There are also data and interoperability issues at hospitals that don’t routinely participate in research.

So if you don’t live in a major centre, participating in the trial requires you to relocate there for the duration of treatment –– the cost of the treatment is covered, but the cost of being in the city where it happens is your responsibility. Patient advocacy groups might be able to help with some of those expenses, but this obviously can be a barrier for a lot of Canadians.

A therapy might only become available to everyone across Canada if a trial is successful and the drug is approved –– but not necessarily, and maybe not anytime soon. More on that next time. Visit BioCanRx.com to learn more.

Finally, the thoroughly hungover shell of Jen Gerson emerges from ten straight days of Calgary Stampede festivities with a political field report. Beneath the parties and pancake breakfasts, she says, the fractures within Canadian conservatism are becoming impossible to ignore. It’s increasingly obvious who is and isn’t willing to speak to whom. What should have been an outstanding month for Alberta Premier Danielle Smith has instead been overshadowed by self-inflicted drama. Meanwhile, Conservative leader Pierre Poilievre continues to struggle against political newcomer Carney. It’s a remarkable — and, in many ways, surprising — dynamic to watch. Wasn't Poilievre supposed to be the political pro who'd mop the floor with the rookie Euro banker? Guess not!

All that and more in the latest episode of The Line Podcast. Check out our main page at ReadTheLine.ca and, always and forever, like and subscribe.

Programming note: The Line is taking a two-week summer holiday. The podcasts will continue, but barring major news events, our page will be quiet for a few weeks. We need a break!

#TheLinePodcast
#MarkCarney
#CanadianPolitics
#CanadaUSRelations
#PipelinePolitics
#DanielleSmith
#PierrePoilievre
#CalgaryStampede
#Geopolitics
#CurrentAffairs

In this episode of On The Line, host Jen Gerson is joined by Andrew Leach, noted energy and environmental economist and professor of economics and law at the University of Alberta, for a conversation about Canadian energy policy at a pivotal moment.

This episode is brought to you by BioCanRx, a federally-funded Canadian not-for-profit research network bringing cutting edge cancer immunotherapy research from Canadian labs to patients in clinical trials –– all in Canada.

A drug that can treat your cancer is being tested in a Canadian clinical trial, but can you access it? Depends — where do you live? Clinical trials taking place in Canada usually open sites in major centers with research hospitals. Smaller hospitals face many challenges including having enough know-how to deliver experimental therapies, and administrative, legal, and regulatory responsibilities that come with a trial. There are also data and interoperability issues at hospitals that don't routinely participate in research.

So if you don’t live in a major centre, participating in the trial requires you to relocate there for the duration of treatment –– the cost of the treatment is covered, but the cost of being in the city where it happens is your responsibility. Patient advocacy groups might be able to help with some of those expenses, but this obviously can be a barrier for a lot of Canadians.

A therapy might only become available to everyone across Canada if a trial is successful and the drug is approved –– but not necessarily, and maybe not anytime soon. More on that next time. Visit BioCanRx.com to learn more.

Recorded on July 2, 2026, just ahead of two major pipeline announcements, the discussion doesn’t cover the specifics of the federal government’s decision to retrace the TMX route or the proposed Canadian Shield pipeline between Alberta and Sarnia. Instead, Gerson and Leach focus on the broader forces shaping Canada’s energy future.

They discuss Prime Minister Mark Carney’s latest Forward Guidance video, the influence of the United States on Canadian energy policy and markets, the promise and limitations of carbon capture and storage, and the political significance of the new Memorandum of Understanding between Alberta and Ottawa. Throughout the conversation, Leach offers his perspective on what has changed — and what hasn’t — in the relationship between governments, industry, and the public.

This episode is also brought to you by the Forest Products Association of Canada. Canada’s forest products sector is not asking Ottawa to start over. The federal government has heard the advice. It has recognized the challenges. And it has put a plan on the table. Now the test is action.

That means clearing made-in-Canada barriers: regulatory duplication, transportation bottlenecks, and uncertainty around predictable access to manage our forests. It means working with provinces to protect communities from wildfire risk and giving companies the confidence to invest here at home. Nearly 200,000 Canadians working in this sector are looking for results.

The playbook is written. Now Ottawa needs to deliver. Learn more at fpac.ca.

The episode also asks a larger question: after decades of political conflict over pipelines, is Canada finally entering a new era? Could this be the beginning of a more grounded conversation about the country’s oil and gas sector, one that focuses less on symbolic battles and more on practical questions of economics, infrastructure, and national interest?

This episode is also brought to you by Cameco. In nuclear energy, timelines and costs matter. Incomplete designs carry real risk of delays and cost overruns. That’s why the AP1000 reactor is the right choice for Canada: it is already operating today and ready now to deliver the power we need, with 100 percent Canadian ownership and strong participation from Canadian suppliers. If we are serious about building Canada and powering it on time and on budget, the choice is clear. The AP1000 reactor is the only option that delivers.

To learn more, visit ap1000.cameco.com.

If you enjoyed the episode, be sure to share it, and as always, like and subscribe to us on your podcast or video app of choice. Be sure to check out our main page at ReadTheLine.ca.

#OnTheLine #AndrewLeach #Energy #Pipelines #TMX #OilAndGas #MarkCarney #Alberta #CanadaPolitics #JenGerson